Abstracts Archive - Page 1470 of 2425 - ACR Meeting Abstracts

Abstract Number: 784 • 2016 ACR/ARHP Annual Meeting
Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE
Kenneth C. Kalunian¹, Murray Urowitz², David A. Isenberg³, Joan T. Merrill⁴, Michelle Petri⁵, Richard Furie⁶, MaryAnn Morgan-Cox⁷, Rebecca Taha⁷, Maria Silk⁷ and Matthew D Linnik⁸, ¹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶North Shore University Hospital, Great Neck, NY, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: SRI is a composite endpoint designed to ensure that clinical improvement (measured by SLEDAI) is not accompanied by deterioration in other organ systems (measured…
Abstract Number: 785 • 2016 ACR/ARHP Annual Meeting
What Is the Prevalence of Cognitive Impairment in Lupus and Which Instruments Are Used to Measure It? a Systematic Review and Meta-Analysis
Hanan Al Rayes¹, Chiara Tani², Marta Mosca², Jorge Medina-Rosas³, Ahmed Moustafa⁴, Panayiotis Lambiris⁵ and Zahi Touma¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ³Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, Western University, London, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: To systematically review literature on: 1) the prevalence of Cognitive Impairment (CI) in SLE patients in the presence or absence of neuropsychiatric involvement (NPSLE),…
Abstract Number: 786 • 2016 ACR/ARHP Annual Meeting
Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Robin Bruchas⁵, Nick Staten⁵, Martin Schmidt⁶, Paul Olson⁵, Chad Stiening⁵ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., Saint Louis, MO, ⁶Kypha, Inc., St. Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 787 • 2016 ACR/ARHP Annual Meeting
Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
Jenna K. Presto^1,2, Jessica S. Haber^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Discoid lupus erythematosus (DLE) progresses to systemic lupus erythematosus (SLE) in up to 28% of cases. The Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 788 • 2016 ACR/ARHP Annual Meeting
Unresolving C4 Hypocomplementemia Associates with a Different Spectrum of Disease in SLE and Is More Important Than Transiently Low Levels
Laura Durcan¹, Wei Fu² and Michelle Petri³, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ³Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hypocomplementemia is common in systemic lupus erythematosus (SLE) and is included in classification criteria and disease activity indices. Whether persistently low complement levels (C3,…
Abstract Number: 789 • 2016 ACR/ARHP Annual Meeting
Use of Nominal Group Technique to Determine Candidate Items for SLE Classification Criteria Development
Sindhu R. Johnson¹, Dinesh Khanna², Ricard Cervera³, Nathalie Costedoat-Chalumeau⁴, Dafna D. Gladman⁵, Bevra H. Hahn⁶, Falk Hiepe⁷, Jorge Sanchez-Guerrero⁸, Elena Massarotti⁹, Dimitrios Boumpas¹⁰, Karen H. Costenbader¹¹, David I. Daikh¹², David Jayne¹³, Thomas Dörner¹⁴, Diane L. Kamen¹⁵, Marta Mosca¹⁶, Rosalind Ramsey-Goldman¹⁷, Josef S. Smolen¹⁸, David Wofsy¹⁹ and Martin Aringer²⁰, ¹Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²University of Michigan, Ann Arbor, MI, ³Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ⁴Internal Medicine, Cochin University Hospital, Paris, France, ⁵Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁷Charité – Universitätsmedizin, Berlin, Germany, ⁸University of Toronto, Toronto, Canada; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁹Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ¹⁰University of Athens, Athens, Greece, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ¹³Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom, ¹⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ¹⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ¹⁶Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ¹⁷FSM, Northwestern University, Chicago, IL, ¹⁸Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁹University of California, San Francisco, San Francisco, CA, ²⁰Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose: Criteria for the classification of SLE are being developed with the support of EULAR and ACR. Two independent exercises (expert-based Delphi exercise and data-driven…
Abstract Number: 790 • 2016 ACR/ARHP Annual Meeting
Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study
Vera Golder¹, Molla Huq², Kate Franklyn³, Alicia Calderone⁴, Aisha Lateef⁵, Chak Sing Lau⁶, Sandra V. Navarra⁷, Timothy Godfrey^4,8, Shereen Oon⁴, Alberta Y. Hoi³, Eric F Morand³, Mandana Nikpour⁹ and Asia Pacific Lupus Collaboration, ¹Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁴St. Vincent’s Hospital, Melbourne, Australia, ⁵Medicine/Rheumatology, National University Health System, Singapore, Singapore, ⁶Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ⁷Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁸63 Sutton Street, St. Vincent’s Hospital, Melbourne, Australia, ⁹Melbourne University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) has historically lacked clear treat-to-target definitions. The recently reported Lupus Low Disease Activity State (LLDAS) definition, combining disease activity and…
Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Edward K.L. Chan¹, Jan Damoiseaux², Gabriel Carballo³, Karsten Conrad⁴, Wilson de Melo Cruvinel⁵, Paulo Francescantonio⁵, Marvin J. Fritzler⁶, Ignacio Garcia-De La Torre⁷, Manfred Herold⁸, Tsuneyo Mimori⁹, Minoru Satoh¹⁰, Carlos Von Muhlen¹¹, Luis E C Andrade¹² and representing committee and translation team members, ¹Dept of Oral Biology, University of Florida, Gainesville, FL, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Hospital Carlos G. Durand, Buenos Aires, Argentina, ⁴Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Pontifícia Universidade Católica de Goiás, Goiânia, Brazil, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁸Medical University of Innsbruck, Innsbruck, Austria, ⁹Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Rheumatology, Rheuma Clinic Dr. von Muhlen, Porto Alegre, Brazil, ¹²Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…
Abstract Number: 792 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
R Furie¹, L Wang², J Drappa² and G Illei², ¹Northwell Health, Great Neck, NY, ²MedImmune, Gaithersburg, MD
Background/Purpose: Post-hoc analysis of two Phase III studies of belimumab1 showed that an SRI(4) response is associated with clinically meaningful benefits, irrespective of treatment assignment.…
Abstract Number: 793 • 2016 ACR/ARHP Annual Meeting
Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity
Christopher Sjöwall¹, Chelsea Bentow², Mary Ann Aure², Gabriella Lakos², Peter Martis² and Michael Mahler², ¹Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ²Research and Development, Inova Diagnostics, San Diego, CA
Multi-parametric model development for assessing lupus nephritis and disease activity Christopher Sjӧwall1, Chelsea Bentow2, Mary Ann Aure2, Gabriella Lakos2, Peter Martis2, Michael Mahler2 1AIR/Rheumatology, Department…
Abstract Number: 794 • 2016 ACR/ARHP Annual Meeting
Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
Zahi Touma¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: It is challenging to describe disease activity in SLE in the context of multiple levels of glucocorticoids (GC) treatment. We aim to develop and…
Abstract Number: 795 • 2016 ACR/ARHP Annual Meeting
Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?
Chiara Tani¹, Roberta Vagelli¹, Chiara Stagnaro², Linda Carli^3,4, Viola Signorini⁵ and Marta Mosca¹, ¹Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ³GenOMec PhD, University of Siena, Italy, ⁴Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁵Rheumatology Unit, Pisa, Italy
Background/Purpose: To date, there is no generally accepted definition for remission in SLE, thus a possible goal in the treat-to-target strategy might be low disease…
Abstract Number: 796 • 2016 ACR/ARHP Annual Meeting
Establishment of an International Autoantibody Standard for Anti-DFS70/LEDGF Antibodies: Proof-of-Concept Study for a Novel Strategy for the Setting up of International Autoantibody Standards
Alessandra Dellavance¹, Danielle Baldo¹ and Luis Eduardo C. Andrade², ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil
Background/Purpose: Robust, certified, and traceable reference material for autoantibody testing is vital for the validity of results obtained in the clinical laboratory. International standards for…
Abstract Number: 797 • 2016 ACR/ARHP Annual Meeting
Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Niti Goel^1,2, Brandon Barrett³, Ann Duncan⁴, Margaret-Beth Gallagher¹ and Marsha Mackey³, ¹Quintiles, Inc., Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Quintiles, Inc., Rockville, MD, ⁴Quintiles, Inc., Reading, Berkshire, United Kingdom
Background/Purpose: Background/Purpose: Randomized controlled trials (RCTs) in SLE identify specific populations of interest for eligibility, but still vary in the recruited populations. These differences may…
Abstract Number: 798 • 2016 ACR/ARHP Annual Meeting
Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus
Subroto Chatterjee¹, Michelle Petri², Steven Jones³ and Vignesh Sadras¹, ¹Pediatrics-Cardiology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Oxidized Phospholipids, Lipoprotein (a) and Glycosphingolipid Associated B- 1,4 Galactosyltransferase in a Johns Hopkins cohort of patients with Systemic Lupus Erythematosus. Background/Purpose: Systemic lupus erythematosus(SLE)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].